Overview
- An FDA advisory committee voted Thursday to recommend adding BPC-157 and KPV to the list of peptides that specialized U.S. pharmacies may compound, passing the measures by an 8–6 margin with one abstention.
- The committee considered seven peptides in total, but its votes to permit BPC-157 and KPV conflict with the agency's own scientists, who told the panel that clinical trial evidence is insufficient to show these products are safe or effective for people.
- Peptides are short chains of amino acids that act as biological messengers, and the two recommended products are widely marketed online and promoted by influencers despite lacking large human trials.
- Critics have raised concerns about the committee's makeup, saying Health Secretary Robert Kennedy Jr. appointed members with industry ties, and warned that loosening pharmacy rules could increase patient exposure to low-quality or harmful products.
- The advisory opinion is non-binding but often influential; if the FDA follows it, legal pharmacy access would likely rise, telemedicine and retail firms could expand sales, and regulators and clinicians would face new demands to monitor safety and product quality.